Sign In

Login

Password

Forgot Password ? Sign Up

Choroba Crohna (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Choroba Crohna" in Polish language version.

refsWebsite
Global rank Polish rank
41nih.gov
4th place
7th place
39doi.org
2nd place
6th place
4web.archive.org
1st place
1st place
2europa.eu
68th place
31st place
1emedicine.com
3,595th place
1,361st place
1chorobacrohna.pl
low place
low place
1crohns.org
low place
low place
1medicalnewstoday.com
3,011th place
4,141st place
1liv.ac.uk
low place
low place
1archive.is
87th place
5th place
1pulsmedycyny.com.pl
low place
low place
1clinicaltrials.gov
5,225th place
3,508th place
1medreviews.com
low place
low place
1worldcat.org
5th place
2nd place

archive.is

chorobacrohna.pl

clinicaltrials.gov

crohns.org

doi.org

dx.doi.org

  • B.B. Crohn, L. Ginzburg, G.D. Oppenheimer, Regional ileitis: a pathologic and clinical entity, „Journal of the American Medical Association”, 99, 1932, s. 1323-1329 (ang.). (przedruk: „The American Journal of Medicine”, 13 (5), 1952, s. 583–590, DOI: 10.1016/0002-9343(52)90025-9, PMID: 12996536 (ang.).)
  • Severine Vermeire, NOD2/CARD15: relevance in clinical practice, „Best Practice & Research. Clinical Gastroenterology”, 18 (3), 2004, s. 569–575, DOI: 10.1016/j.bpg.2003.12.008, PMID: 15157828 (ang.).
  • Jean-Pierre Hugot i inni, Prevalence of CARD15/NOD2 mutations in Caucasian healthy people, „The American Journal of Gastroenterology”, 102 (6), 2007, s. 1259–1267, DOI: 10.1111/j.1572-0241.2007.01149.x, PMID: 17319929 (ang.).
  • Giulia Roda i inni, Intestinal epithelial cells in inflammatory bowel diseases, „World Journal of Gastroenterology”, 16 (34), 2010, s. 4264–4271, DOI: 10.3748/wjg.v16.i34.4264, PMID: 20818809, PMCID: PMC2937106 (ang.).
  • Laurent Peyrin-Biroulet i inni, Crohn's disease: beyond antagonists of tumour necrosis factor, „The Lancet”, 372 (9632), 2008, s. 67–81, DOI: 10.1016/S0140-6736(08)60995-2, PMID: 18603161 (ang.).
  • Rodrigue Dessein, Mathias Chamaillard, Silvio Danese, Innate immunity in Crohn's disease: the reverse side of the medal, „Journal of Clinical Gastroenterology”, 42 Suppl 3 Pt 1, 2008, S144–S147, DOI: 10.1097/MCG.0b013e3181662c90, PMID: 18806708 (ang.).
  • R. Balfour Sartor, Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis, „Nature Clinical Practice. Gastroenterology & Hepatology”, 3 (7), 2006, s. 390–407, DOI: 10.1038/ncpgasthep0528, PMID: 16819502 (ang.).
  • Saleh A. Naser, Michael T. Collins, Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn's disease, „Inflammatory Bowel Diseases”, 11 (12), 2005, s. 1123, DOI: 10.1097/01.mib.0000191609.20713.ea, PMID: 16306778 (ang.).
  • M.H. Giaffer, A. Clark, C.D. Holdsworth, Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance, „Gut”, 33 (8), 1992, s. 1071–1075, DOI: 10.1136/gut.33.8.1071, PMID: 1398231, PMCID: PMC1379444 (ang.).
  • Martin Baumgart i inni, Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum, „The ISME journal”, 1 (5), 2007, s. 403–418, DOI: 10.1038/ismej.2007.52, PMID: 18043660 (ang.).
  • G.P. Gui i inni, Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics, „The Journal of Antimicrobial Chemotherapy”, 39 (3), 1997, s. 393–400, DOI: 10.1093/jac/39.3.393, PMID: 9096189 (ang.).
  • Nicolas Cenac i inni, Role for protease activity in visceral pain in irritable bowel syndrome, „The Journal of Clinical Investigation”, 117 (3), 2007, s. 636–647, DOI: 10.1172/JCI29255, PMID: 17304351, PMCID: PMC1794118 (ang.).
  • Nicolas Cenac i inni, Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2, „The American Journal of Pathology”, 161 (5), 2002, s. 1903–1915, DOI: 10.1016/S0002-9440(10)64466-5, PMID: 12414536, PMCID: PMC1850779 (ang.).
  • Kenneth F. Boorom i inni, Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection, „Parasites & Vectors”, 1 (1), 2008, s. 40, DOI: 10.1186/1756-3305-1-40, PMID: 18937874, PMCID: PMC2627840 (ang.).
  • Jean-Pierre Hugot i inni, Crohn's disease: the cold chain hypothesis, „The Lancet”, 362 (9400), 2003, s. 2012–2015, DOI: 10.1016/S0140-6736(03)15024-6, PMID: 14683664 (ang.).
  • Alastair Forbes, Tommy Kalantzis, Crohn's disease: the cold chain hypothesis, „International Journal of Colorectal Disease”, 21 (5), 2006, s. 399–401, DOI: 10.1007/s00384-005-0003-7, PMID: 16059694 (ang.).
  • Sreedhar Subramanian i inni, Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics, „Antimicrobial Agents and Chemotherapy”, 52 (2), 2008, s. 427–434, DOI: 10.1128/AAC.00375-07, PMID: 18070962, PMCID: PMC2224732 (ang.).
  • Chiedzo M. Mpofu i inni, Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease, „Gastroenterology”, 133 (5), 2007, s. 1487–1498, DOI: 10.1053/j.gastro.2007.08.004, PMID: 17919633 (ang.).
  • S.B. Hanauer, Inflammatory bowel disease, „The New England Journal of Medicine”, 334 (13), 1996, s. 841–848, DOI: 10.1056/NEJM199603283341307, PMID: 8596552 (ang.).
  • M.H. Mueller i inni, Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease, „The British Journal of Surgery”, 89 (8), 2002, s. 1027–1031, DOI: 10.1046/j.1365-2168.2002.02173.x, PMID: 12153630 (ang.).
  • Patrick Chamouard i inni, Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease, „Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association”, 4 (7), 2006, s. 882–887, DOI: 10.1016/j.cgh.2006.02.003, PMID: 16630759 (ang.).
  • Brinderjit Kaila, Kenneth Orr, Charles N. Bernstein, The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease, „Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie”, 19 (12), 2005, s. 717–721, DOI: 10.1155/2005/147681, PMID: 16341311 (ang.).
  • E. Israeli i inni, Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease, „Gut”, 54 (9), 2005, s. 1232–1236, DOI: 10.1136/gut.2004.060228, PMID: 16099791, PMCID: PMC1774672 (ang.).
  • Asher Kornbluth, David B. Sachar, Practice Parameters Committee of the American College of Gastroenterology, Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee, „The American Journal of Gastroenterology”, 99 (7), 2004, s. 1371–1385, DOI: 10.1111/j.1572-0241.2004.40036.x, PMID: 15233681 (ang.).
  • S.B. Hanauer, W. Sandborn, Practice Parameters Committee of the American College of Gastroenterology, Management of Crohn's disease in adults, „The American Journal of Gastroenterology”, 96 (3), 2001, s. 635–643, DOI: 10.1111/j.1572-0241.2001.3671_c.x, PMID: 11280528 (ang.).
  • Ulrika Broomé, Annika Bergquist, Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer, „Seminars in Liver Disease”, 26 (1), 2006, s. 31–41, DOI: 10.1055/s-2006-933561, PMID: 16496231 (ang.).
  • C. Canavan, K.R. Abrams, J. Mayberry, Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, „Alimentary Pharmacology & Therapeutics”, 23 (8), 2006, s. 1097–1104, DOI: 10.1111/j.1365-2036.2006.02854.x, PMID: 16611269 (ang.).
  • A. Ekbom i inni, Increased risk of large-bowel cancer in Crohn's disease with colonic involvement, „The Lancet”, 336 (8711), 1990, s. 357–359, DOI: 10.1016/0140-6736(90)91889-i, PMID: 1975343 (ang.).
  • E.F. Stange i inni, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, „Gut”, 55 Suppl 1, 2006, i1–i15, DOI: 10.1136/gut.2005.081950a, PMID: 16481628, PMCID: PMC1859998 (ang.).
  • T.P. van Staa i inni, 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study, „Gut”, 54 (11), 2005, s. 1573–1578, DOI: 10.1136/gut.2005.070896, PMID: 15994215, PMCID: PMC1774734 (ang.).
  • Jeffrey Tang i inni, Mesalamine protects against colorectal cancer in inflammatory bowel disease, „Digestive Diseases and Sciences”, 55 (6), 2010, s. 1696–1703, DOI: 10.1007/s10620-009-0942-x, PMID: 19705280 (ang.).
  • William J. Sandborn i inni, Certolizumab pegol for the treatment of Crohn's disease, „The New England Journal of Medicine”, 357 (3), 2007, s. 228–238, DOI: 10.1056/NEJMoa067594, PMID: 17634458 (ang.).
  • Dulce Soler i inni, The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases, „The Journal of Pharmacology and Experimental Therapeutics”, 330 (3), 2009, s. 864–875, DOI: 10.1124/jpet.109.153973, PMID: 19509315 (ang.).
  • Brian G. Feagan i inni, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin, „Clinical Gastroenterology and Hepatology”, 6 (12), 2008, s. 1370–1377, DOI: 10.1016/j.cgh.2008.06.007, PMID: 18829392 (ang.).
  • C. Prantera i inni, Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin, „Alimentary Pharmacology & Therapeutics”, 23 (8), 2006, s. 1117–1125, DOI: 10.1111/j.1365-2036.2006.02879.x, PMID: 16611272 (ang.).
  • Jill P. Smith i inni, Low-dose naltrexone therapy improves active Crohn's disease, „The American Journal of Gastroenterology”, 102 (4), 2007, s. 820–828, DOI: 10.1111/j.1572-0241.2007.01045.x, PMID: 17222320 (ang.).
  • D. Brustolim i inni, A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice, „International Immunopharmacology”, 6 (6), 2006, s. 903–907, DOI: 10.1016/j.intimp.2005.12.007, PMID: 16644475 (ang.).
  • Eric Lewin Altschuler, Richard E. Kast, Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha?, „Psychosomatic Medicine”, 65 (4), 2003, s. 719, DOI: 10.1097/01.psy.0000073874.55003.ee, PMID: 12883127 (ang.).
  • Timna Naftali i inni, Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study, „Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association”, 11 (10), 2013, 1276–1280.e1, DOI: 10.1016/j.cgh.2013.04.034, PMID: 23648372 (ang.).

emedicine.com

  • Leyla J. Ghazi, Crohn Disease, eMedicine, 26 lipca 2019 [dostęp 2020-03-14] (ang.).

europa.eu

ec.europa.eu

ema.europa.eu

liv.ac.uk

medicalnewstoday.com

medreviews.com

nih.gov

ncbi.nlm.nih.gov

  • B.B. Crohn, L. Ginzburg, G.D. Oppenheimer, Regional ileitis: a pathologic and clinical entity, „Journal of the American Medical Association”, 99, 1932, s. 1323-1329 (ang.). (przedruk: „The American Journal of Medicine”, 13 (5), 1952, s. 583–590, DOI: 10.1016/0002-9343(52)90025-9, PMID: 12996536 (ang.).)
  • Severine Vermeire, NOD2/CARD15: relevance in clinical practice, „Best Practice & Research. Clinical Gastroenterology”, 18 (3), 2004, s. 569–575, DOI: 10.1016/j.bpg.2003.12.008, PMID: 15157828 (ang.).
  • Jean-Pierre Hugot i inni, Prevalence of CARD15/NOD2 mutations in Caucasian healthy people, „The American Journal of Gastroenterology”, 102 (6), 2007, s. 1259–1267, DOI: 10.1111/j.1572-0241.2007.01149.x, PMID: 17319929 (ang.).
  • Giulia Roda i inni, Intestinal epithelial cells in inflammatory bowel diseases, „World Journal of Gastroenterology”, 16 (34), 2010, s. 4264–4271, DOI: 10.3748/wjg.v16.i34.4264, PMID: 20818809, PMCID: PMC2937106 (ang.).
  • Laurent Peyrin-Biroulet i inni, Crohn's disease: beyond antagonists of tumour necrosis factor, „The Lancet”, 372 (9632), 2008, s. 67–81, DOI: 10.1016/S0140-6736(08)60995-2, PMID: 18603161 (ang.).
  • Rodrigue Dessein, Mathias Chamaillard, Silvio Danese, Innate immunity in Crohn's disease: the reverse side of the medal, „Journal of Clinical Gastroenterology”, 42 Suppl 3 Pt 1, 2008, S144–S147, DOI: 10.1097/MCG.0b013e3181662c90, PMID: 18806708 (ang.).
  • R. Balfour Sartor, Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis, „Nature Clinical Practice. Gastroenterology & Hepatology”, 3 (7), 2006, s. 390–407, DOI: 10.1038/ncpgasthep0528, PMID: 16819502 (ang.).
  • Saleh A. Naser, Michael T. Collins, Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn's disease, „Inflammatory Bowel Diseases”, 11 (12), 2005, s. 1123, DOI: 10.1097/01.mib.0000191609.20713.ea, PMID: 16306778 (ang.).
  • M.H. Giaffer, A. Clark, C.D. Holdsworth, Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance, „Gut”, 33 (8), 1992, s. 1071–1075, DOI: 10.1136/gut.33.8.1071, PMID: 1398231, PMCID: PMC1379444 (ang.).
  • Martin Baumgart i inni, Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum, „The ISME journal”, 1 (5), 2007, s. 403–418, DOI: 10.1038/ismej.2007.52, PMID: 18043660 (ang.).
  • G.P. Gui i inni, Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics, „The Journal of Antimicrobial Chemotherapy”, 39 (3), 1997, s. 393–400, DOI: 10.1093/jac/39.3.393, PMID: 9096189 (ang.).
  • Nicolas Cenac i inni, Role for protease activity in visceral pain in irritable bowel syndrome, „The Journal of Clinical Investigation”, 117 (3), 2007, s. 636–647, DOI: 10.1172/JCI29255, PMID: 17304351, PMCID: PMC1794118 (ang.).
  • Nicolas Cenac i inni, Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2, „The American Journal of Pathology”, 161 (5), 2002, s. 1903–1915, DOI: 10.1016/S0002-9440(10)64466-5, PMID: 12414536, PMCID: PMC1850779 (ang.).
  • Kenneth F. Boorom i inni, Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection, „Parasites & Vectors”, 1 (1), 2008, s. 40, DOI: 10.1186/1756-3305-1-40, PMID: 18937874, PMCID: PMC2627840 (ang.).
  • Jean-Pierre Hugot i inni, Crohn's disease: the cold chain hypothesis, „The Lancet”, 362 (9400), 2003, s. 2012–2015, DOI: 10.1016/S0140-6736(03)15024-6, PMID: 14683664 (ang.).
  • Alastair Forbes, Tommy Kalantzis, Crohn's disease: the cold chain hypothesis, „International Journal of Colorectal Disease”, 21 (5), 2006, s. 399–401, DOI: 10.1007/s00384-005-0003-7, PMID: 16059694 (ang.).
  • Sreedhar Subramanian i inni, Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics, „Antimicrobial Agents and Chemotherapy”, 52 (2), 2008, s. 427–434, DOI: 10.1128/AAC.00375-07, PMID: 18070962, PMCID: PMC2224732 (ang.).
  • Chiedzo M. Mpofu i inni, Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease, „Gastroenterology”, 133 (5), 2007, s. 1487–1498, DOI: 10.1053/j.gastro.2007.08.004, PMID: 17919633 (ang.).
  • S.B. Hanauer, Inflammatory bowel disease, „The New England Journal of Medicine”, 334 (13), 1996, s. 841–848, DOI: 10.1056/NEJM199603283341307, PMID: 8596552 (ang.).
  • M.H. Mueller i inni, Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease, „The British Journal of Surgery”, 89 (8), 2002, s. 1027–1031, DOI: 10.1046/j.1365-2168.2002.02173.x, PMID: 12153630 (ang.).
  • Patrick Chamouard i inni, Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease, „Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association”, 4 (7), 2006, s. 882–887, DOI: 10.1016/j.cgh.2006.02.003, PMID: 16630759 (ang.).
  • Brinderjit Kaila, Kenneth Orr, Charles N. Bernstein, The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease, „Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie”, 19 (12), 2005, s. 717–721, DOI: 10.1155/2005/147681, PMID: 16341311 (ang.).
  • E. Israeli i inni, Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease, „Gut”, 54 (9), 2005, s. 1232–1236, DOI: 10.1136/gut.2004.060228, PMID: 16099791, PMCID: PMC1774672 (ang.).
  • Asher Kornbluth, David B. Sachar, Practice Parameters Committee of the American College of Gastroenterology, Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee, „The American Journal of Gastroenterology”, 99 (7), 2004, s. 1371–1385, DOI: 10.1111/j.1572-0241.2004.40036.x, PMID: 15233681 (ang.).
  • S.B. Hanauer, W. Sandborn, Practice Parameters Committee of the American College of Gastroenterology, Management of Crohn's disease in adults, „The American Journal of Gastroenterology”, 96 (3), 2001, s. 635–643, DOI: 10.1111/j.1572-0241.2001.3671_c.x, PMID: 11280528 (ang.).
  • Ulrika Broomé, Annika Bergquist, Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer, „Seminars in Liver Disease”, 26 (1), 2006, s. 31–41, DOI: 10.1055/s-2006-933561, PMID: 16496231 (ang.).
  • C. Canavan, K.R. Abrams, J. Mayberry, Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, „Alimentary Pharmacology & Therapeutics”, 23 (8), 2006, s. 1097–1104, DOI: 10.1111/j.1365-2036.2006.02854.x, PMID: 16611269 (ang.).
  • A. Ekbom i inni, Increased risk of large-bowel cancer in Crohn's disease with colonic involvement, „The Lancet”, 336 (8711), 1990, s. 357–359, DOI: 10.1016/0140-6736(90)91889-i, PMID: 1975343 (ang.).
  • E.F. Stange i inni, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, „Gut”, 55 Suppl 1, 2006, i1–i15, DOI: 10.1136/gut.2005.081950a, PMID: 16481628, PMCID: PMC1859998 (ang.).
  • T.P. van Staa i inni, 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study, „Gut”, 54 (11), 2005, s. 1573–1578, DOI: 10.1136/gut.2005.070896, PMID: 15994215, PMCID: PMC1774734 (ang.).
  • Jeffrey Tang i inni, Mesalamine protects against colorectal cancer in inflammatory bowel disease, „Digestive Diseases and Sciences”, 55 (6), 2010, s. 1696–1703, DOI: 10.1007/s10620-009-0942-x, PMID: 19705280 (ang.).
  • William J. Sandborn i inni, Certolizumab pegol for the treatment of Crohn's disease, „The New England Journal of Medicine”, 357 (3), 2007, s. 228–238, DOI: 10.1056/NEJMoa067594, PMID: 17634458 (ang.).
  • Dulce Soler i inni, The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases, „The Journal of Pharmacology and Experimental Therapeutics”, 330 (3), 2009, s. 864–875, DOI: 10.1124/jpet.109.153973, PMID: 19509315 (ang.).
  • Brian G. Feagan i inni, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin, „Clinical Gastroenterology and Hepatology”, 6 (12), 2008, s. 1370–1377, DOI: 10.1016/j.cgh.2008.06.007, PMID: 18829392 (ang.).
  • C. Prantera i inni, Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin, „Alimentary Pharmacology & Therapeutics”, 23 (8), 2006, s. 1117–1125, DOI: 10.1111/j.1365-2036.2006.02879.x, PMID: 16611272 (ang.).
  • David T. Rubin, Asher Kornblunth, Role of antibiotics in the management of inflammatory bowel disease: a review, „Reviews in Gastroenterological Disorders”, 5 Suppl 3, 2005, S10–S15, ISSN 1533-001X, PMID: 17713454 [dostęp 2020-03-12] (ang.).
  • Jill P. Smith i inni, Low-dose naltrexone therapy improves active Crohn's disease, „The American Journal of Gastroenterology”, 102 (4), 2007, s. 820–828, DOI: 10.1111/j.1572-0241.2007.01045.x, PMID: 17222320 (ang.).
  • D. Brustolim i inni, A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice, „International Immunopharmacology”, 6 (6), 2006, s. 903–907, DOI: 10.1016/j.intimp.2005.12.007, PMID: 16644475 (ang.).
  • Eric Lewin Altschuler, Richard E. Kast, Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha?, „Psychosomatic Medicine”, 65 (4), 2003, s. 719, DOI: 10.1097/01.psy.0000073874.55003.ee, PMID: 12883127 (ang.).
  • Timna Naftali i inni, Treatment of Crohn's disease with cannabis: an observational study, „The Israel Medical Association Journal”, 13 (8), 2011, s. 455–458, PMID: 21910367 (ang.).
  • Timna Naftali i inni, Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study, „Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association”, 11 (10), 2013, 1276–1280.e1, DOI: 10.1016/j.cgh.2013.04.034, PMID: 23648372 (ang.).

pulsmedycyny.com.pl

web.archive.org

worldcat.org